MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market

SEOUL, South Korea, Sept. 26, 2026 /PRNewswire/ -- MAYPHARM, a global aesthetic and cosmeceutical company, has announced the upcoming launch of HYALMASS AQUATOX, introducing a new multi-active formulation designed to respond to the rapidly evolving demands of the global aesthetic market.

Rather than relying on a single trending ingredient, HYALMASS AQUATOX brings together five high-interest active ingredients — PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid — in one advanced aesthetic formulation.

Five Powerful Actives. One Advanced Formula.

Botulinum Peptide — designed to support a smoother, more refined skin appearance

GHK-Cu — a copper peptide widely studied for skin conditioning and regeneration-related applications

Succinic Acid — recognized for its role in skin revitalization and antioxidant-related activity

PDRN — associated with skin regeneration and recovery

Exosomes — increasingly recognized for their role in advanced skin rejuvenation approaches

By combining these highly sought-after ingredients, HYALMASS AQUATOX aims to address the growing global demand for multifunctional, ingredient-driven aesthetic solutions.

A New Chapter for the HYALMASS Portfolio

The launch follows the growing international interest in HYALMASS AQUA EXOSOME, strengthening MAYPHARM's expanding presence in the global aesthetic market.

As demand for advanced skin rejuvenation products continues to develop, the market has also seen an increasing number of products adopting similar ingredient concepts, visual identities, and positioning. MAYPHARM therefore emphasizes the importance of product authenticity and authorized distribution when purchasing HYALMASS products.

Distributors, aesthetic professionals, and customers are encouraged to verify the original manufacturer, authorized supply channel, packaging, and official product information before purchasing or using HYALMASS products.

Innovation That Moves With the Market

With HYALMASS AQUATOX, MAYPHARM continues to expand its portfolio around emerging aesthetic trends while combining multiple high-interest actives into a single product concept.

Five actives. One formula. A new direction for advanced skin care.

HYALMASS AQUATOX — Coming Soon.

Choose the Original. Choose MAYPHARM.

SOURCE Maypharm

Share this article

Patterson & O'Neill Partner Chris Manasserian Named a Southern California Commercial Real Estate Visionary by LA Times Studios

SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- The real estate law firm of Patterson & O'Neill today announced partner Chris Manasserian has been named one of Southern California's Commercial Real Estate Business Visionaries by LA Times Studios.

The annual recognition highlights accomplished senior leaders across Southern California's commercial real estate industry, including developers, architects, brokers, engineers, contractors and professional advisors. This year's honorees were selected based on standout achievements over the past two years, sustained excellence throughout their careers, impact on their organizations and the broader industry and civic engagement.

Manasserian recently joined Patterson & O'Neill as a partner, bringing extensive experience in California land use, entitlements, environmental law and real estate development.

Throughout his career, Manasserian has helped entitle millions of square feet of residential, commercial, mixed-use, industrial, and hotel development. His work includes advising clients on entitlement strategy, zoning and planning, CEQA compliance, subdivisions, the Starter Home Revitalization Act, the State Density Bonus Law, and other state housing laws.

"Chris has built an impressive career helping clients navigate some of California's most complex land use and development challenges, and this recognition reflects the depth of experience and leadership he brings to the industry," said Ryan Patterson, Managing Partner at Patterson & O'Neill. "We are proud to have him as a partner at the firm and look forward to the continued impact he will have on our clients and communities across California."

Read Manasserian's LA Times Studios profile here.

In 2025 Patterson & O'Neill founding partners Ryan J. Patterson and Brian O'Neill were named to The Daily Journal's list of "Top Real Estate and Real Estate Development Lawyers." The annual special report recognizes leading California attorneys whose work is shaping the state's real estate and housing landscape.

Patterson and O'Neill were honored for their groundbreaking litigation enforcing California's pro-housing laws and clearing the way for badly needed new housing throughout the state. In recent years, the firm secured a series of high-impact trial court victories against the City of Los Angeles that are expected to result in approvals for hundreds of new homes, including many reserved for low-income residents.

The firm's successes spurred Patterson & O'Neill to open a Los Angeles office in the historic Fine Arts Building in downtown Los Angeles, positioning the team close to City Hall and key trial courts as they continue to represent housing advocates and developers in high-stakes disputes.

About Patterson & O'Neill, PC

Patterson & O'Neill, PC is a California-based law firm focused on land use, real estate and environmental law. The firm represents developers, property owners, businesses and other clients navigating complex land use and real estate matters throughout the state. Its attorneys advise clients on land use entitlements, state housing laws, environmental review, permitting and real estate litigation, providing strategic counsel through complex state and local regulatory processes.

For more information, visit https://pattersononeill.com/

Andrea Pulgarin

[email protected]

415-718-4545

SOURCE Patterson & O'Neill, PC

Share this article

IRVINE, Calif., Sept. 25, 2026 /PRNewswire/ -- Sunwest Bank has acquired Nano Banc of Irvine, California in an FDIC-assisted acquisition. The Federal Deposit Insurance Corporation (FDIC) accepted receivership of Nano Banc from the Department of Financial Protection and Innovation (DFPI), which closed Nano Banc on Friday, September 25th. The FDIC subsequently entered into an agreement with Sunwest Bank, under which Sunwest agreed to acquire substantially all the deposits and a portion of assets of Nano Banc. The assumed deposits total approximately $605 million and assumed loans total $227 million.

Nano Banc customers will have immediate access to their deposits. Over the weekend, they can access their deposits by writing checks, using ATMs or through their debit cards. Checks drawn on Nano Banc will continue to be processed. All loan customers should continue to make their payments as usual. The former Nano Banc will reopen as Sunwest Bank on Monday, September 28th.

"We are honored to once again to be selected by the FDIC as the acquiring institution of an FDIC-assisted acquisition, marking the sixth time Sunwest Bank has completed such a transaction," said Carson Lappetito, President and CEO of Sunwest Bank. "This opportunity reflects the financial strength, disciplined management, and stability that have defined Sunwest Bank for more than five decades. We are excited to welcome Nano Banc's customers to Sunwest and show them the high-touch service, advanced technology and sophistication we offer to our clients."

Customers with questions should contact the FDIC toll-free at 1-866-314-1744 or visit the FDIC Website at FDIC.GOV. This phone number will be operational this evening until 8:00 p.m., Pacific Time (PT); on Saturday from 9:00 a.m. to 5:00 p.m., PT; Sunday from noon to 12:00 p.m. to 4:00 p.m., PT; Monday from 8:00 a.m. to 5:00 p.m., PT, and thereafter, weekdays from 8:00 a.m. to 4:00 p.m., PT.

About Sunwest Bank

Founded in 1969, Sunwest Bank is a privately held commercial bank with over $5.0 billion in assets. With a growing presence throughout the United States, Sunwest is headquartered in Sandy, Utah, with offices across California, Arizona, Idaho, Colorado, Utah, and Florida. The bank partners with businesses,

individuals, and entrepreneurs nationwide to deliver leading banking services including technology forward treasury management, commercial and real estate lending products, and corporate financial solutions.

With a strong capital position and a commitment to innovation, Sunwest Bank continues to challenge traditional banking models through forward-thinking initiatives designed to support its clients' growth and long-term success. Sunwest Bank operates with a Fortress Balance Sheet, long-term outlook, and has an impeccable track record of supporting their clients through all economic cycles.

SOURCE Sunwest Bank

Share this article

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time

PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026.

The webcast can be accessed at the following link DAYBREAK Topline Results Webcast or from the Events and Presentations page on Kodiak's website at https://ir.kodiak.com/events-and-presentations/events.

An archived replay of the webcast will be available for a limited time.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.

Kodiak®, Kodiak Sciences®, ABC®, ABC Platform™, Zenkuda™, VETi™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

SOURCE Kodiak Sciences Inc.

Share this article

WASHINGTON, Sept. 25, 2026 /PRNewswire/ -- MedStar Health and Monumental Sports & Entertainment (MSE) are proud to continue their philanthropic partnership supporting some of the District's most vulnerable residents.

Through a $1.1 million donation, MSE will continue funding MedStar Health services providing specialized care to birthing mothers, infants, and children of all ages in Washington, D.C.

In 2024, MSE pledged annual philanthropic support over five years to help expand access to this potentially life-saving care.

"We offer gratitude to our partners at Monumental Sports & Entertainment for their continued support," said Kenneth A. Samet, FACHE, president and CEO of MedStar Health. "Caring for our communities is a team sport, and alongside great teammates, we are proud to be there for our young families where they need us and when they need us."

"Sports teams have a responsibility to give back to the communities they call home and to be there for families when they need support most. That commitment is at the heart of our longstanding partnership with MedStar Health," said Ted Leonsis, founder, chairman, managing partner and CEO of Monumental Sports & Entertainment. "MedStar Health is delivering incredibly important care for mothers and children across Washington, D.C., and has been an exceptional partner in helping us deliver meaningful impact by improving the health and strength of our community."

Women and Infant Services

Support for MedStar Health's Safe Babies Safe Moms program connects birthing mothers to prenatal care, nutrition support, parenting education, and mental health resources beginning before pregnancy and continuing until a child turns three.

Through community partnerships, the program also helps with transportation, housing, and legal support.

According to a recent study, many women cared for by Safe Babies Safe Moms are less likely to have low birthweight babies and preterm births.

"Achieving better outcomes for mothers and babies is a national issue that we are gaining ground on through Safe Babies Safe Moms," said Angela D. Thomas DrPH, MPH, vice president of Healthcare Delivery Research at MedStar Health Research Institute. "Partners like Monumental Sports & Entertainment who help sustain this life-saving work are invaluable."

MSE's gift will also support MedStar Health's Mother-Baby Intensive Outpatient program for pregnant and postpartum mothers with mood and anxiety disorders.

Community Pediatrics

MSE continues its transformative support for the MedStar Health Kids Mobile Medical Clinic, which has provided thousands of children across the District with convenient access to high-quality and affordable primary care for more than 30 years.

The clinic's medical and wellbeing units make weekly stops to neighborhoods in D.C. Wards 6 and 7, seeing about 800 patients each year. Families are never billed for services.

Care teams also screen for challenges related to food insecurity, housing, education, income, and community safety.

Two years ago, support from MSE helped the clinic maintain its second wellbeing unit, dedicated to screening families for food insecurity, housing, education, income, and community safety. Both units received state-of-the-art functional and clinical upgrades, as well as a fresh blue-and-maize exterior featuring logos of the Washington Wizards, Mystics, Capitals, and Capital City Go-Go.

"We share Monumental Sports & Entertainment's vision to create a Washington, D.C., that is healthy and thriving for everybody. I am proud to serve alongside them on behalf of this community," said Janine A. Rethy, MD, MPH, division chief of Community Pediatrics and medical director of the MedStar Health Kids Mobile Medical Clinic.

Since 2019, MSE and The Leonsis Family have provided more than $13 million in philanthropic support to MedStar Health initiatives, including women and infant services, pediatric community health, COVID-19 response, the MedStar Health Center for Wellbeing, and the sports medicine program at MedStar Health Lafayette Centre.

SOURCE MedStar Health

Share this article

PUNE, India, Sept. 25, 2026 /PRNewswire/ -- Global N95 Mask Market was valued at USD 3.27 Billion in 2025 and is projected to grow at a 14.52% CAGR from 2026 to 2034, reaching USD 11.08 Billion by 2034, according to Maximize Market Research.

Global N95 Mask Market

The Global N95 Mask Market Report 2026 examines market growth, respiratory protection demand, workplace safety regulations, healthcare usage, industrial applications, infection-control requirements, product types, end-user demand, regional trends, competitive developments, and market forecasts through 2034. The market is segmented by Uses, Product Type, End User, and Region, covering reusable and disposable N95 masks, products with and without exhalation valves, and demand across healthcare, industrial, household, government, and defense applications.

The market is growing as hospitals, industrial workplaces, emergency-response teams, and individuals place greater emphasis on protection from airborne particles, infectious diseases, dust, chemicals, and hazardous contaminants. Stringent workplace safety requirements, rising healthcare activity, infection-control needs, and continued demand for respiratory protection are supporting N95 mask consumption across major markets.

Demand is also being shaped by wider use of N95 respirators in manufacturing, mining, construction, healthcare facilities, emergency response, and public protection. At the same time, counterfeit products, low-quality masks, supply constraints, and intense price competition remain important challenges. These factors are expected to influence the N95 Mask Market as it grows from USD 3.27 Billion in 2025 to USD 11.08 Billion by 2034 at a CAGR of 14.52%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/105931/

Global N95 Mask Market gains momentum as healthcare providers, industrial employers, governments, and consumers strengthen respiratory protection measures, while workplace safety regulations and rising awareness of airborne health risks continue to support market growth, says Maximize Market Research.

Global N95 Mask Market Size & Forecast

Global N95 Mask Market Trends & Insights

- North America leads the Global N95 Mask Market, supported by strong healthcare demand, workplace safety requirements, infection-control measures, and the presence of major respirator manufacturers. The region accounted for the largest share in 2025, while continued investment in production capacity and respiratory protection supports its market position.

- Workplace safety regulations and healthcare use remain major demand drivers. Hospitals, clinics, industrial facilities, and emergency-response environments rely on N95 respirators to protect workers from airborne pathogens, dust, chemicals, and hazardous particles. Growth in medical procedures and infection-prevention requirements is also supporting steady demand.

- Healthcare and industrial applications are shaping product demand. N95 masks are widely used by doctors, nurses, manufacturing workers, miners, construction teams, government agencies, defense personnel, and households seeking protection from pollution, allergens, and contagious diseases.

- Disposable and reusable N95 masks serve different usage needs, while products with and without exhalation valves are selected according to application. Disposable masks remain important in healthcare and infection-control settings, while valve-based respirators are commonly suited to industrial environments requiring prolonged respiratory protection.

- Asia Pacific is emerging as a high-growth regional market, supported by government efforts to expand protective-mask production, strengthen supply, and improve emergency preparedness. At the same time, counterfeit products, low-quality masks, supply shortages, and pricing pressures remain important challenges for the Global N95 Mask Market through 2034.

Workplace Safety Rules and Healthcare Demand Drive Market Growth

The N95 Mask Market is expanding as hospitals, clinics, industrial facilities, and emergency-response teams place greater emphasis on respiratory protection. Stringent workplace safety regulations, rising surgical activity, ICU admissions, and infection-control requirements are supporting demand for N95 respirators. Industrial users in manufacturing, mining, construction, oil & gas, and petrochemicals also rely on N95 masks to reduce exposure to dust, smoke, hazardous particles, and other airborne contaminants.

Counterfeit Products and Supply Constraints Restrain Market Growth

The market continues to face pressure from counterfeit and low-quality N95 masks, which can weaken buyer confidence and create safety concerns. The RD also highlights competition from low-cost products and periods of limited N95 availability. Supply shortages and sharp price increases during periods of elevated demand can make procurement more difficult for healthcare providers, governments, and industrial users.

Healthcare Expansion and Industrial Respiratory Protection Create Opportunities

Growing use of N95 masks across healthcare, manufacturing, mining, construction, government, defense, and household applications is creating broader opportunities for manufacturers. Government support for protective-mask production, expansion of manufacturing capacity, and stronger distribution through online and offline channels are also improving market reach. Asia Pacific presents additional growth potential as governments and manufacturers invest in production capacity and respiratory-protection supply.

Quality, Authenticity, and Supply Reliability Remain Key Challenges

Maintaining product quality, verifying authenticity, and ensuring reliable supply remain important challenges in the N95 Mask Market. Manufacturers and distributors must respond to concerns around fake respirators, pricing pressure, demand fluctuations, and shortages while supplying healthcare and industrial users that depend on consistent filtration performance and respiratory protection. Building trusted distribution networks and maintaining dependable production capacity will remain important for long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/105931/

Global N95 Mask Market Segmentation

The Global N95 Mask Market is segmented by Uses, Product Type, End User, and Region. The market covers reusable and disposable respirators, N95 masks with and without exhalation valves, and demand across healthcare, industrial, household, government, and defense applications. Product selection varies according to usage conditions, filtration needs, hygiene requirements, duration of wear, and exposure to airborne particles or infectious agents.

North America Leads the N95 Mask Market as Asia Pacific Records the Fastest Growth

North America is the leading region in the Global N95 Mask Market, supported by strong healthcare demand, workplace safety requirements, infection-control needs, and the presence of major respiratory protection manufacturers. The region remains a major market for N95 respirators, disposable N95 masks, reusable N95 masks, healthcare PPE, industrial respiratory protection, and protective face masks, with companies such as 3M, Honeywell, Moldex-Metric, Cardinal Health, and Medline Industries maintaining a significant presence.

Asia Pacific is emerging as the fastest-growing regional market, with the RD citing a 29.55% CAGR during the forecast period. Demand for N95 masks is being supported by government efforts to strengthen protective-mask production, expand manufacturing capacity, secure raw materials, and improve respiratory protection preparedness. China, Japan, India, South Korea, Australia, and other Asia Pacific markets form part of the regional coverage.

Europe remains part of the global N95 mask market, with demand spanning healthcare, industrial safety, and respiratory protection applications. The region includes the UK, France, Germany, Italy, Spain, Sweden, Austria, and the rest of Europe, with companies such as Drägerwerk, JSP, Paul Hartmann, and Freudenberg active across respiratory protection, PPE, and filtration materials.

South America and the Middle East & Africa are also included in the Global N95 Mask Market, covering Brazil, Argentina, South Africa, GCC countries, Egypt, Nigeria, and other regional markets. These regions form part of the broader global demand base for N95 masks, respirators, healthcare protection, industrial safety products, and infection-prevention equipment.

Leading Companies Strengthen the Global N95 Mask Market

The N95 Mask Market includes a broad mix of medical respirator manufacturers, industrial respiratory protection companies, disposable mask producers, healthcare PPE suppliers, and filtration-material companies. Key names in the RD include 3M Company, Honeywell International, Moldex-Metric, Drägerwerk, Winner Medical, MSA Safety, JSP, Kimberly-Clark, Cardinal Health, Medline Industries, Paul Hartmann, Berry Global, Freudenberg, Toray Industries, and Asahi Kasei.

These companies compete across medical N95 respirators, disposable N95 masks, industrial respirators, filtering facepiece respirators, healthcare PPE, nonwoven filtration materials, and workplace respiratory protection products. Market reach is also supported by online and offline distribution networks involving major distributors such as Henry Schein, Fisher Scientific, Amazon, W.W. Grainger, and Westnet.

Global N95 Mask Market Competitive Landscape

Competition in the Global N95 Mask Market is shaped by product quality, filtration performance, manufacturing capacity, distribution reach, pricing, healthcare demand, and industrial safety requirements.

PUNE, India, Sept. 25, 2026 /PRNewswire/ -- The Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research.

Global AI in Clinical Trials Market

The Global AI in Clinical Trials Market Report 2026 provides a detailed assessment of market trends, clinical research activity, AI adoption, patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, trial-phase applications, end-user demand, competitive developments, and market forecasts through 2034. The market is segmented by Trial Phase, Technology, Application, End-Users, and Region, covering Phase I, Phase II, and Phase III trials; machine learning, natural language processing, and deep learning; and applications including patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

The market is expanding as pharmaceutical and biotechnology companies increasingly use AI to improve the speed and efficiency of clinical research. AI tools are being applied to patient screening, cohort selection, trial design, large-scale data analysis, safety evaluation, and treatment optimization. By analyzing complex patient datasets, AI can help researchers identify suitable trial participants, detect patterns more quickly, and support more targeted clinical decision-making.

Growing use of machine learning, deep learning, AI-driven patient monitoring, real-world evidence, decentralized trials, and AI-enabled drug discovery is creating new opportunities across the clinical research ecosystem. Pharmaceutical companies, CROs, hospitals, and research institutes are adopting AI to streamline workflows, improve patient recruitment, strengthen data quality, and reduce delays in drug development. These developments are expected to support the AI in Clinical Trials Market as it grows from USD 2 Billion in 2025 to USD 7.32 Billion by 2034 at a CAGR of 15.5%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/222597/

Global AI in Clinical Trials Market gains momentum as pharmaceutical companies, CROs, and research institutions turn to AI for faster patient recruitment, smarter data analysis, improved safety monitoring, personalized medicine, and more efficient drug development, says Maximize Market Research.

Global AI in Clinical Trials Market Size & Forecast

Global AI in Clinical Trials Market Trends & Insights

- North America leads the Global AI in Clinical Trials Market, supported by strong healthcare infrastructure, a mature pharmaceutical industry, significant investment in AI research, and increasing collaboration between pharmaceutical and technology companies. The United States remains the key regional market, while Europe is also seeing rapid adoption across the UK, Germany, and France.

- AI adoption is reshaping patient recruitment and clinical trial operations by helping researchers identify suitable participants, analyze large patient datasets, improve cohort selection, and support trial design. These capabilities are helping reduce delays and improve the efficiency of clinical research.

- Machine learning, natural language processing, and deep learning are becoming central technologies across the AI in Clinical Trials Market. Their use is expanding in patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine across Phase I, Phase II, and Phase III trials.

- Pharmaceutical and biotechnology companies remain major adopters of AI in clinical research, using the technology to support drug discovery, trial execution, data analysis, and post-market surveillance. CROs, hospitals, research institutes, and government agencies are also increasing adoption as AI becomes more embedded in the clinical research ecosystem.

- Decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery are emerging as important market trends. Growing use of AI in diagnostics, treatment optimization, patient stratification, and personalized medicine is expected to create new opportunities as the Global AI in Clinical Trials Market advances toward 2034.

Faster Patient Recruitment and Data Analysis Drive Market Growth

The AI in Clinical Trials Market is gaining momentum as pharmaceutical companies, biotechnology firms, CROs, and research organizations look for faster and more efficient ways to manage clinical studies. AI is increasingly being used for patient screening, cohort selection, trial design, data analysis, and recruitment, helping researchers identify suitable participants and process large volumes of clinical information more quickly. These capabilities are improving trial efficiency while supporting faster drug development and better use of research resources.

Data Privacy, Regulatory Compliance, and Data Quality Restrain Adoption

Despite its potential, AI adoption in clinical trials faces important barriers. Data privacy concerns, regulatory compliance, data quality issues, and the need for specialized AI expertise can slow implementation across clinical research organizations. Because clinical trials handle sensitive patient information and operate under strict regulatory requirements, companies must ensure that AI systems are reliable, transparent, and supported by high-quality data before they can be widely integrated into trial workflows.

Decentralized Trials and AI-Driven Drug Discovery Create New Opportunities

The growing use of decentralized clinical trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery is opening new opportunities across the market. Machine learning, deep learning, and natural language processing are being applied to patient recruitment, safety monitoring, personalized medicine, and drug discovery. As AI becomes more deeply embedded in clinical research, companies have greater scope to improve trial design, identify treatment-responsive patient groups, and accelerate development of new therapies.

AI Expertise, Trust, and Reliable Clinical Data Remain Key Challenges

A major challenge for the AI in Clinical Trials Market is ensuring that AI-generated insights are supported by accurate, high-quality clinical data and can be used responsibly in regulated research environments. Organizations also need the right technical expertise to apply AI across trial phases and therapeutic areas. As AI adoption expands, maintaining data integrity, regulatory compliance, patient privacy, and confidence in AI-supported decision-making will remain central to long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/222597/

Global AI in Clinical Trials Market Segmentation

The Global AI in Clinical Trials Market is segmented by Trial Phase, Technology, Application, End-Users, and Region. The market covers AI adoption across Phase I, Phase II, and Phase III clinical trials, with technologies such as machine learning, natural language processing, and deep learning supporting patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, research institutes, CROs, hospitals, and other end-users are increasingly integrating AI into clinical research workflows.

North America Leads the AI in Clinical Trials Market as Asia Pacific Gains Ground

North America leads the Global AI in Clinical Trials Market, supported by advanced healthcare infrastructure, a well-established pharmaceutical industry, strong investment in AI research, and growing collaboration between drug developers and technology companies. The United States remains the key market as AI is increasingly used for patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

Europe is also seeing steady adoption of AI in clinical research, particularly across the UK, Germany, and France. Strong pharmaceutical capabilities, established regulatory systems, government support for healthcare AI, and cross-border research partnerships are helping expand the use of machine learning and digital technologies in clinical trials.

Asia Pacific is emerging as an important market, led by China, India, and Japan. Large patient populations, expanding pharmaceutical sectors, and growing interest in more efficient and affordable clinical research are encouraging wider adoption of AI. Japan's advanced technology ecosystem is also creating opportunities for AI-driven healthcare and clinical trial applications.

South America and the Middle East & Africa remain developing markets for AI in Clinical Trials. Expanding pharmaceutical activity, improving healthcare infrastructure, evolving regulatory frameworks, and partnerships with international research and pharmaceutical organizations are supporting gradual adoption across these regions.

Leading Companies Expand the AI in Clinical Trials Market

Euretos, Biosymetrics, Unlearn.AI, Exscientia, AiCure, Antidote Technologies, Deep 6 AI, Innoplexus, IQVIA, Medidata, Mendel.ai, Phesi, Saama Technologies, Signant Health, Trials.ai, and other participants are active across the AI in Clinical Trials Market. These companies are developing solutions for patient recruitment, clinical data analysis, trial optimization, safety monitoring, and AI-supported drug development.

Global AI in Clinical Trials Market Competitive Landscape

Competition in the Global AI in Clinical Trials Market is becoming more technology-driven as companies focus on machine learning, deep learning, natural language processing, AI-powered patient recruitment, predictive analytics, and personalized medicine.

Concurrent DARPA awards provide non-dilutive funding to accelerate MagLev Aero's path to TRL-6 flight readiness, de-risking dual-use commercialization and advancing U.S.-manufactured propulsion for American "Drone Dominance" initiatives.

BOSTON, Sept. 25, 2026 /PRNewswire/ -- Propulsion has always been at the core of aircraft performance. As defense drones undergo a rapid performance escalation on the modern battlefield, there remains a critical, unmet need for advanced propulsion systems capable of establishing true drone air dominance. Addressing this challenge, MagLev Aero, a pioneer in advanced aerospace propulsion technology, today announced it has been selected by the Defense Advanced Research Projects Agency (DARPA) for concurrent awards under the Minimum Viable Product (MVP) and Embedded Entrepreneur Initiative (EEI) programs.

MagLev Aero has created a breakthrough in propulsion technology that provides more thrust for less power, fundamentally changing the physics of flight. This highly efficient architecture directly enables higher speeds, longer operational ranges, increased payload capacities, and a dramatically reduced noise signature—all the key domains required for drones that must evade detection and capture, counter-drones designed to catch and kill hostile threats, and cargo drones for contested logistics.

Supported by this non-dilutive government funding and an accelerating defense-market demand signal, MagLev Aero is advancing the industrialization of its next-generation propulsion platform. The platform is purpose-built to meet the surging demand for high-performance, U.S.-manufactured drone propulsion, aligning directly with White House "Drone Dominance" priorities, and the rapidly expanding commercial advanced air mobility (AAM) market. DARPA funding will support rapid advancement from prototype to flight-tested production, significantly reducing technical and integration risks for dual-use commercialization.

DARPA MVP - Accelerating Flight Readiness for Airframers

DARPA's MVP support helps technology developers quickly prototype, test, and adapt breakthroughs. MagLev Aero is funded to build and test a full-scale, flight-relevant propulsion demonstration platform, culminating in a Technology Readiness Level 6 (TRL-6) demonstration in a relevant operational environment. This effort significantly de-risks adoption for airframers and OEMs developing the next generation of autonomous drones and crewed aircraft by demonstrating:

DARPA EEI - Scaling U.S. Industrialization & Commercialization

Simultaneously, the DARPA EEI Program accelerates MagLev Aero's defense commercialization, go-to-market execution, and U.S. industrialization strategy. The award funds the embedding of an experienced business leader to help navigate federal acquisition frameworks and capture strategic transition opportunities.

"These dual DARPA contracts represent a major inflection point for MagLev Aero," said Ian Randall, Co-Founder and CEO of MagLev Aero. "We are not just proving out physics in a lab; we are helping build the propulsion industrial base for the next generation of American air power. By rapidly advancing our scalable, domestically manufactured propulsion platform to TRL-6, we are delivering a proven solution that meets the urgent national need for trusted, high-performance U.S. drone technologies."

About MagLev Aero

MagLev Aero is a Boston-based company developing the MagLev HyperDrive™ propulsion platform for the next generation of drones and advanced air vehicles. Backed by Breakthrough Energy Ventures and Material Impact, with 44 issued patents, its rim-driven ducted fan architecture leverages its patented MagLev HyperDrive™ technology. The company is devising a new engineering framework combining modern AI compute technology, multiphysics optimization, and human innovation to accelerate electrified propulsion design. The goal: unlock unprecedented levels of efficiency, range, payload, noise reduction, speed, and resiliency, directly enhancing operational capabilities for both defense and commercial aircraft applications.

Disclaimer: Any opinions, findings, conclusions, or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Defense Advanced Research Projects Agency (DARPA).

Ian Randall

Co-Founder & CEO

linkedin.com/in/ian-randall-maglevaero

Media & Investor Contact:

Kerry Brackett

[email protected]

www.maglevaero.com

https://www.linkedin.com/company/maglev-aero/

SOURCE MagLev Aero

Share this article

WEBCO INDUSTRIES, INC. REPORTS FISCAL 2026 FOURTH QUARTER AND YEAR END RESULTS

SAND SPRINGS, Okla., Sept. 25, 2026 /PRNewswire/ -- Webco Industries, Inc. (OTC: WEBC) today reported results for our fourth fiscal quarter and year ended July 31, 2026.

For our fourth quarter of fiscal year 2026, we had net income of $5.0 million, or $7.35 per diluted share, while in our fourth quarter of fiscal year 2025, we had net income of $6.5 million, or $9.18 per diluted share. Net sales for the fourth quarter of fiscal 2026 were $189.7 million, a 19.9 percent increase from the $158.2 million in sales in the fourth quarter of fiscal year 2025.

For fiscal year 2026, we generated net income of $18.3 million, or $26.50 per diluted share, compared to a net income of $9.3 million, or $12.30 per diluted share, in fiscal year 2025. Net sales for the current fiscal year totaled $670.9 million, a 14.8 percent increase from the $584.7 million in sales for last year.

In the fourth quarter of fiscal year 2026, we had income from operations of $7.7 million after depreciation of $5.1 million. The fourth fiscal quarter of the prior year generated income from operations of $9.0 million after depreciation of $4.8 million. Gross profit for the fourth quarter of fiscal 2026 was $27.7 million, or 14.6 percent of net sales, compared to $22.0 million, or 13.9 percent of net sales, for the fourth quarter of fiscal year 2025.

Our income from operations for fiscal year 2026 was $28.0 million, after depreciation expense of $20.0 million. Income from operations in fiscal year 2025 was $16.6 million, after depreciation expense of $19.0 million. Gross profit for fiscal 2026 was $94.0 million, or 14.0 percent of net sales, compared to $66.8 million, or 11.4 percent of net sales for fiscal year 2025.

Selling, general and administrative expenses were $20.0 million in the fourth quarter of fiscal 2026 and $12.9 million in the fourth quarter of fiscal 2025. SG&A expenses were $66.0 million in fiscal year 2026 and $50.2 million for fiscal year 2025. SG&A expenses reflect increases in costs related to higher profitability, such as company-wide incentive compensation and variable pay programs, plus inflation we have experienced in wages and other expenses.

Interest expense was $1.5 million in the fourth quarter of fiscal year 2026 and $1.4 million in the same quarter of fiscal year 2025. Interest expense was $5.9 million and $5.3 million in the current and prior fiscal years, respectively. Interest expense increased due to higher average debt balances than in the prior fiscal periods.

Capital expenditures incurred amounted to $1.8 million in the fourth quarter of fiscal year 2026 and $15.4 million for fiscal year 2026. Capital spending in fiscal year 2026 has been focused on plant equipment updates and improvements.

At July 31, 2026, we had $9.1 million in cash and short-term investments, in addition to $112.9 million of available borrowing under our $220 million senior revolving credit facility. Availability on the revolver, which had $89.3 million drawn at July 31, 2026, is subject to advance rates on eligible accounts receivable and inventories. In February 2026, we extended the maturity on our debt agreement to February 2031. Accounting rules require asset-based debt agreements like our revolver to be classified as a current liability, despite its fiscal year 2031 maturity.

Webco's stock repurchase program authorizes the purchase of our outstanding common stock in private or open market transactions. In March 2026, the Company's Board of Directors refreshed the repurchase program with a new limit of up to $6.0 million and extended the program's expiration until July 31, 2029. We purchased 11,900 shares of our stock during the fourth quarter of fiscal year 2026 and 33,800 shares in fiscal year 2026. At July 31, 2026, there was approximately $1.6 million of purchase authority left in the current stock repurchase program. The repurchase plan may be extended, suspended or discontinued at any time, without notice, at the Board's discretion.

Webco's mission is to continuously build on our strengths as we create a vibrant company for the ages. We leverage our core values of trust and teamwork, continuously building strength, agility and innovation. We focus on practices that support our brand such that we are 100% engaged every day to build a forever kind of company for our Trusted Teammates, customers, business partners, investors and community. We provide high-quality carbon steel, stainless steel and other metal specialty tubing products designed to industry and customer specifications. We have five tube production facilities in Oklahoma and Pennsylvania and eight value-added facilities in Oklahoma, Illinois, Michigan, Pennsylvania and Texas, serving customers globally. Our F. William Weber Leadership Campus is in Sand Springs, Oklahoma and houses our corporate offices and our Webco TechCenter™, providing a state-of-the-art laboratory and R & D facility to lead and develop technical solutions for the metal tubing industry.

Risk Factors and Forward-looking statements: Certain statements in this release, including, but not limited to, those preceded by or predicated upon the words "anticipates," "appears," "believes," "estimates," "expects," "forever," "hopes," "intends," "plans," "projects," "pursue," "should," "will," "wishes," or similar words may constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievements expressed or implied herein. Such risks, uncertainties and factors include the factors discussed above and, among others: general economic and business conditions, including any global economic downturn; government policy or low hydrocarbon prices that stifle domestic investment in energy; competition from foreign imports, including any impacts associated with dumping or the strength of the U.S. dollar; political or social environments that are unfriendly to industrial or energy-related businesses; changes in manufacturing technology; the banking environment, including availability of adequate financing; worldwide and domestic monetary policy; changes in tax rates and regulation; regulatory and permitting requirements, including, but not limited to, environmental, workforce, healthcare, safety and national security; availability and cost of adequate qualified and competent personnel; changes in import / export tariff or restrictions; volatility in raw material cost and availability for the Company, its customers and vendors; the cost and availability, including time for delivery, of parts and services necessary to maintain equipment essential to the Company's manufacturing activities; the cost and availability of manufacturing supplies, including process gases; volatility in oil, natural gas and power cost and availability; world-wide or national transition from hydrocarbon sources of energy that adversely impact demand for our products; problems associated with product development efforts; significant shifts in product demand away from internal combustion engine automobiles; appraised values of inventories that can impact available borrowing under the Company's credit facility; declaration of material adverse change by a lender; industry capacity; domestic competition; loss of, or reductions in, purchases by significant customers and customer work stoppages; work stoppages by critical suppliers; labor unrest; conditions, including acts of God, that require more costly transportation of raw materials; accidents, equipment failures and insured or uninsured casualties; third-party product liability claims; flood, tornado, winter storms and other natural disasters; customer or supplier bankruptcy; customer or supplier declarations of force majeure; customer or supplier breach of contract; insurance cost and availability; lack of insurance coverage for floods; the cost associated with providing healthcare benefits to employees; customer claims; supplier quality or delivery problems; technical and data processing capabilities; cyberattack on our information technology infrastructure; world, domestic or regional health crises; vaccine mandates or related governmental policy that would cause significant portions of our workforce, or that of our customers or vendors, to leave their current employment; global or regional wars and conflicts; our inability or unwillingness to comply with rules required to maintain the quotation of our shares on any market place; and our inability to repurchase the Company's stock. The Company assumes no obligation to publicly update any such forward-looking statements. No assurance is provided that current results are indicative of those that will be realized in the future.

TABLES FOLLOW

SOURCE Webco Industries, Inc.

Share this article

SOUTHLAKE, Texas, Sept. 25, 2026 /PRNewswire/ -- Sabre Corporation ("Sabre") (Nasdaq: SABR) today announced the early tender results of the previously announced cash tender offer (the "Tender Offer") by Sabre Financial Borrower, LLC ("Sabre Financial"), its indirect wholly-owned subsidiary, for any and all of Sabre Financial's securities set forth in the table below (the "Securities") and concurrent solicitation of consents (the "Consent Solicitation") to certain proposed amendments to the Securities and the Indenture (as defined below). The Tender Offer and Consent Solicitation will expire at 5:00 p.m., New York City time, on October 12, 2026 (unless extended or earlier terminated, the "Expiration Date").

The Tender Offer and Consent Solicitation are being made pursuant to the terms and conditions set forth in the offer to purchase and consent solicitation statement, dated September 14, 2026 (the "Offer to Purchase").

As of 5:00 p.m., New York City time, on September 25, 2026 (such date and time, the "Early Tender Deadline" and "Withdrawal Deadline," as applicable), according to information provided to D.F. King & Co., Inc., the tender and information agent for the Tender Offer and Consent Solicitation, the aggregate principal amount of Securities listed in the table below has been validly tendered and not validly withdrawn in the Tender Offer and Consent Solicitation. Withdrawal rights for the Securities expired at the Early Tender Deadline and, accordingly, any Securities that were validly tendered may no longer be withdrawn except where additional withdrawal rights are required by law.

The Tender Offer and Consent Solicitation remain subject to the satisfaction or waiver of the conditions described in the Offer to Purchase, including the financing for the Tender Offer and Consent Solicitation. Such conditions may be waived by Sabre Financial in its sole discretion, subject to applicable law. Any waiver of a condition by Sabre Financial will not constitute a waiver of any other condition. Subject to the satisfaction or waiver of such conditions and as described in the Offer to Purchase, Sabre Financial is expected to make payment on September 28, 2026 (such date and time, as it may be extended, the "Early Settlement Date") for the Securities and related consents that (i) were validly tendered and delivered, as applicable, and not validly withdrawn or revoked, as applicable, at or prior to the Early Tender Deadline and (ii) are accepted for purchase on the Early Settlement Date.

The consideration to be paid for the Securities accepted for purchase on the Early Settlement Date per $1,000 principal amount of Securities is the amount set forth in the table above under the heading "Total Consideration." The amounts set forth in the table above under "Total Consideration" include an early tender premium of $50 per $1,000 principal amount of Securities accepted for purchase (the "Early Tender Premium"). All Holders of Securities accepted for purchase will also receive accrued and unpaid interest from the most recent interest payment date preceding the Early Settlement Date to, but not including, the Early Settlement Date.

Any Holder who tenders Securities in the Tender Offer and Consent Solicitation will be deemed to automatically have provided consents, and Securities may not be tendered without delivering consents. Based on the consents received as of the Early Tender Deadline, Sabre Financial has obtained the required consents to effect all of the proposed amendments (the "Proposed Amendments") as described in the Offer to Purchase. Consequently, as previously announced, Sabre Financial expects to execute a supplemental indenture (the "Supplemental Indenture") effecting the Proposed Amendments with respect to the indenture dated December 5, 2025 (the "Indenture"), entered into by and among Sabre Financial, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, under which the Securities were issued, and the Securities on or about the Early Settlement Date. The Supplemental Indenture will become effective upon (a) its execution and delivery by each of the parties thereto, and (b) the settlement of the Tender Offer with respect to accepted Securities tendered prior to the Early Tender Deadline on the Early Settlement Date.

In addition, pursuant to the terms of the Indenture, because more than 90% of the aggregate principal amount of the Securities outstanding has been validly tendered in the Tender Offer, Sabre Financial intends, following its purchase of the tendered Securities, to deliver a notice of redemption to redeem all Securities that remain outstanding after giving effect to the purchase of the Securities on the Early Settlement Date. The redemption price for such Securities will be equal to the Total Consideration set forth in the table above, plus accrued and unpaid interest thereon to, but excluding, the redemption date. The redemption date is expected to be October 13, 2026. Notwithstanding the foregoing, there can be no assurance that any Securities will be redeemed. Nothing herein shall constitute a notice of redemption with respect to the Securities.

Sabre Financial reserves the right, subject to applicable law, in its sole discretion, to waive any of the conditions of the Tender Offer or the Consent Solicitation, in whole or in part, at any time and from time to time. It also reserves the right, subject to applicable law, in its sole discretion, (1) to terminate or withdraw the Tender Offer or the Consent Solicitation at any time; (2) to extend the Early Tender Deadline, the Withdrawal Deadline or the Expiration Date; or (3) otherwise to amend the Tender Offer or Consent Solicitation in any respect. It may extend the Early Tender Deadline without extending the Withdrawal Deadline.

Information Relating to the Tender Offer and Consent Solicitation

The complete terms and conditions of the Tender Offer and Consent Solicitation are set forth in the Offer to Purchase. BofA Securities is the Dealer Manager and Solicitation Agent for the Tender Offer and Consent Solicitation. Investors with questions regarding the Tender Offer and Consent Solicitation may contact BofA Securities, collect: (980) 388-3646, toll-free: (888) 292-0070, email: [email protected]. D.F. King & Co., Inc. is the tender and information agent for the Tender Offer and Consent Solicitation. Copies of the Offer to Purchase and any related offer documents may be obtained by contacting D.F. King & Co., Inc. by phone at (646) 455-1060 (New York) or (866) 356-7814 (toll-free) or by email at [email protected].

None of Sabre Financial, Sabre, their affiliates, their respective boards of directors and stockholders, the Dealer Manager and Solicitation Agent, the Tender Agent or Wilmington Trust, National Association, as trustee for the Securities, are making any recommendation as to whether Holders should tender any Securities or deliver any Consent in response to the Tender Offer and Consent Solicitation. Holders must make their own decision as to whether to tender any of their Securities and deliver their Consents, and, if so, the principal amount of Securities to tender and Consents to deliver.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any of the Securities, and the Tender Offer and Consent Solicitation do not constitute offers to buy or the solicitation of offers to sell Securities in any jurisdiction or in any circumstances in which such offers are unlawful. The full details of the Tender Offer and Consent Solicitation, including complete instructions on how to tender Securities and deliver Consents, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase because it will contain important information.

Forward-Looking Statements

Certain statements herein are forward-looking statements about trends, future events, uncertainties and our plans and expectations of what may happen in the future. Any statements that are not historical or current facts are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "expect," "guidance," "outlook," "trend," "pro forma," "on course," "on track," "target," "potential," "benefit," "goal," "believe," "plan," "confident," "anticipate," "indicate," "trend," "position," "optimistic," "will," "forecast," "continue," "strategy," "estimate," "project," "may," "should," "would," "intend," or the negative of these terms, where applicable, or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. More information about potential risks and uncertainties that could materially affect our business and results of operations is included in the "Risk Factors" and "Forward-Looking Statements" sections in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 18, 2026 and in our other filings with the SEC, as well as other risks and uncertainties specified in the "Certain Significant Considerations" section of the Offer to Purchase. We cannot guarantee future events, including financing of the Tender Offer and Consent Solicitation and successful completion of the Tender Offer and Consent Solicitation, outlook, guidance, results, actions, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements.